Literature DB >> 22869573

In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.

Manoj Kumar1, Tarun Mathur, Tarani K Barman, G Ramkumar, Ashish Bhati, Gunjan Shukla, Vandana Kalia, Manisha Pandya, V Samuel Raj, Dilip J Upadhyay, Chetana Vaishnavi, Anjan Chakrabarti, Biswajit Das, Pradip K Bhatnagar.   

Abstract

The MIC(90) of RBx 14255, a novel ketolide, against Clostridium difficile was 4 μg/ml (MIC range, 0.125 to 8 μg/ml), and this drug was found to be more potent than comparator drugs. An in vitro time-kill kinetics study of RBx 14255 showed time-dependent bacterial killing for C. difficile. Furthermore, in the hamster model of C. difficile infection, RBx 14255 demonstrated greater efficacy than metronidazole and vancomycin, making it a promising candidate for C. difficile treatment.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22869573      PMCID： PMC3486553          DOI： 10.1128/AAC.00015-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.

Authors:  F Barbut; A Richard; K Hamadi; V Chomette; B Burghoffer; J C Petit
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study.

Authors:  Scott Modena; Dilip Bearelly; Kenneth Swartz; Frank K Friedenberg
Journal:  Infect Control Hosp Epidemiol       Date:  2005-08       Impact factor: 3.254

3.  Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study.

Authors:  D N Gerding; M M Olson; L R Peterson; D G Teasley; R L Gebhard; M L Schwartz; J T Lee
Journal:  Arch Intern Med       Date:  1986-01

4.  Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile.

Authors:  Tarun Mathur; Manoj Kumar; Tarani K Barman; G Ram Kumar; Vandana Kalia; Smita Singhal; V Samuel Raj; Dilip J Upadhyay; Biswajit Das; Pradip K Bhatnagar
Journal:  J Antimicrob Chemother       Date:  2011-03-03       Impact factor: 5.790

5.  Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.

Authors:  Vandana Kalia; Rajni Miglani; Kedar P Purnapatre; Tarun Mathur; Smita Singhal; Seema Khan; Sreedhara R Voleti; Dilip J Upadhyay; Kulvinder Singh Saini; Ashok Rattan; V Samuel Raj
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Inappropriate testing for diarrheal diseases in the hospital.

Authors:  D L Siegel; P H Edelstein; I Nachamkin
Journal:  JAMA       Date:  1990-02-16       Impact factor: 56.272

8.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

Authors:  Fred A Zar; Srinivasa R Bakkanagari; K M L S T Moorthi; Melinda B Davis
Journal:  Clin Infect Dis       Date:  2007-06-19       Impact factor: 9.079

9.  Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.

Authors:  Kim L Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

10.  Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.

Authors:  Tetsuya Tanikawa; Toshifumi Asaka; Masato Kashimura; Keiko Suzuki; Hiroyuki Sugiyama; Masakazu Sato; Kazuya Kameo; Shigeo Morimoto; Atsushi Nishida
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446
View more
  4 in total

1.  In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile.

Authors:  Tarun Mathur; Tarani Kanta Barman; Manoj Kumar; Diksha Singh; Ram Kumar; Manoj Kumar Khera; Makiko Yamada; Shin-Ichi Inoue; Dilip Jatashankar Upadhyay; Nobuhisa Masuda
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 2.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

3.  In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile.

Authors:  Daisuke Oka; Naomitsu Yamaya; Takuya Kuno; Yuta Asakawa; Toshiyuki Shiragiku; Liang Chen; Jingbo Xue; Abudusaimi Mamuti; Fangguo Ye; Jiangqin Sun; Kinue Ohguro; Hisashi Miyamoto; Yukitaka Uematsu; Katsuya Inagaki; Jie-Fei Cheng; Makoto Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 4.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.